Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - KERYX BIOPHARMACEUTICALS INC | v233914_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 31, 2011
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
(State or Other Jurisdiction
of Incorporation)
|
000-30929
(Commission File Number)
|
13-4087132
(IRS Employer Identification No.)
|
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act.
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item 8.01. Other Events
On August 31, 2011, Keryx Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that the independent Data Safety Monitoring Board (“DSMB”) for the Company’s pivotal Phase 3 X-PECT study of KRX-0401 (perifosine) in patients with refractory advanced colorectal cancer has completed a pre-specified interim analysis for safety and futility. The independent DSMB has recommended that the Phase 3 study continue to completion, as planned. A copy of such press release is being furnished as Exhibit 99.1 to this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Keryx Biopharmaceuticals, Inc.
(Registrant)
|
|||
|
Date: August 31, 2011
|
By:
|
/s/ James F. Oliviero | |
|
James F. Oliviero
|
|||
|
Chief Financial Officer
|
|||
|
INDEX TO EXHIBITS
|
|
Exhibit
|
|
|
Number
|
Description
|
|
99.1
|
Press Release dated August 31, 2011. |